Bristol Myers Squibb’s Mavacamten, an oral drug, becomes the first cardiac myosin inhibitor that has been approved by the US Food and Drug Administration (FDA). Patients, specifically adults, with symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM) are eligible to be treated by the said drug. Bristols Myers gained Mavacamten from MyoKardia back in 2020 on a buyout at a price of $13 billion. The firm claims Mavacamten will improve functionality and treat symptoms.
Read More from Reuters